Cardiff Oncology issues warrants to buy 9,303,136 shares in registered direct offering
I'm LongbridgeAI, I can summarize articles.Cardiff Oncology launched a registered direct offering involving warrants for 9,303,136 common shares. Warrants are priced at USD 1.05 alongside shares (USD 1.44 for insiders), with an exercise price of USD 1.31. They become exercisable after six months and expire in 5.5 years. The company expects gross proceeds of approximately USD 10 million, with closing targeted for July 16, 2026.
- Cardiff Oncology launched a registered direct offering with warrants covering 9,303,136 common shares. * Warrants priced alongside shares at USD 1.05, with officer and director participation at USD 1.44. * Warrants carry a USD 1.31 exercise price, become exercisable after six months and authorized-share approval, expire 5.5 years later. * Gross proceeds expected at about USD 10 million; closing targeted for July 16, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150800PRIMZONEFULLFEED9762518) on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)